Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Nonprofit Vitamin C Foundation Issues Oral Dosage Recommendations to Achieve Vitamin C Blood Levels that Kill Cancer Stem Cells (CSCs)
  • USA - English


News provided by

Inteligent*Vitamin*C Inc

Nov 06, 2017, 08:50 ET

Share this article

Share toX

Share this article

Share toX

Linus Pauling
Linus Pauling

NAPERVILLE, Ill. (PRWEB) November 06, 2017 -- The nonprofit Vitamin C Foundation is a clearing house and center of expertise regarding this vital nutrient. In this role, the Foundation actively monitors vitamin C research from around the world. Recently, a series of stunning Vitamin C and Cancer research studies have prompted the Foundation's publication of new vitamin C dosage recommendations for cancer patients..

Available studies indicate that vitamin C, at doses of 4 g/kg b.w., a pancreatic tumor mass reduction of more than 40% could be achieved in a xenograft animal model.

Post this

In a study from India, for the first time in the history of science, experienced cancer researchers discovered that different dosages of vitamin C have much different effects on the "seeds" of intestinal cancer. Lower doses spurred colon cancer stem cell (CSC) growth. Optimal doses of vitamin C, and niacin, or vitamin B3, destroy cancer stem cells. Very high dosages, again, promoted CSC proliferation.

The study, published in a peer reviewed journal, Cell Biology International, http://onlinelibrary.wiley.com/doi/10.1002/cbin.10830/full, is the latest in a series of surprising year 2017 research reports supporting Nobel prize laureate Linus Pauling's long-held assertion that vitamin C can be used to prevent, control, and even treat cancer.

The Indian test tube study investigated both low and high doses of vitamin C, and niacin, on stem cell tumors of the intestine. Different dosages produced opposite effects. Dr. Utave. Sen, et. al., found that when taking a dosage that creates concentrations of vitamin C (and vitamin B3) from 5-25 micromoles/liter, a low concentration, there is a process of active reproduction of cancer stem cell tumors of the intestine. At higher dosages (100 to 1,000 micromoles), these stem cells are destroyed.

The Foundations White Paper on constant oral dosing to achieve the necessary CSC-lethal concentrations is now available: https://vitamincfoundation.org/pdfs/CancerWhitePaper.pdf . These recommendations are based on the Sen, et. al., in vitro study findings regarding the optimal concentration of vitamin C and the Vitamin C Foundation's prior knowledge of blood concentrations after oral dosing.

The Sen, et. al., measurements indicate that daily amounts of one gram or less of vitamin C promote CSC proliferation. This new finding indicates that the government approved RDA for Vitamin C, and the low amount currently recommended by the Linus Pauling Institute at Oregon State, are dangerous for cancer patients. Much more vitamin C is needed to avoid CSC proliferation and malignancy relapse, at least 12 grams daily as long recommended by Linus Pauling.

Foundation's Review of the Recent Science from Around the World

People fighting cancer are fighting two different battles. The active malignancy and the more subtle battle against these otherwise hard-to-kill cancer stem cells (CSCs).

In 2001, the University of Michigan Cancer Center proclaimed that current chemotherapy targets the “wrong” cells. The Ann Arbor researchers discovered that not all cells in a tumor are equally malignant. Only tiny minorities of tumor cells are actually capable of inducing new cancers; the rest are relatively harmless. "These tumor-inducing cells have many of the properties of stem cells," said Michael F. Clarke, MD, a professor of internal medicine, who directed the study. "They make copies of themselves --a process called self-renewal -- and produce all the other kinds of cells in the original tumor."

The 2017 first-ever study from India found that vitamin C, and Niacin to a lesser extent, at the proper concentrations can kill CSCs - the seeds of ordinary malignant cells. Importantly, they also demonstrated that too small concentrations of vitamin C (and Niacin) actually promote the proliferation of these cancer-seed cells.

Last June, Professor Michael Lisanti from the University of Salford, UK, published two studies that found vitamin C and antibiotics could be up to 100 times more effective at killing cancer stem cells (CSCs) than standard-of-care drugs. According to Lisanti, giving the antibiotic doxycycline followed by vitamin C effectively starves cancer stem cells of their fuel, resulting in their death in the lab, the researchers said.

Then last August, another research groups located in the UK and USA published their findings that injections of vitamin C could help fight blood cancers. Luisa Cimmino and Benjamin Neel at the New York University School of Medicine and their colleagues have discovered that, by injecting vitamin C, cancer growth could be prevented. Researchers halted the progression of leukemia in mice by promoting the function of a specific gene through high doses of vitamin C.

In the same month, researchers at Children's Medical Center Research Institute at UT Southwestern discovered that stem cells absorb “unusually high” levels of vitamin C, which reportedly regulate function and suppress the development of leukemia. Dr. Michalis Agathocleous, lead author of the study, said stem cells use vitamin C to regulate chemical modifications on DNA, which turn genes on and off. “When stem cells don’t receive enough vitamin C, these [DNA-regulating mechanisms] can become damaged in a way that increases stem cell function but also increases the risk of leukemia.” Thus, if humans take up more vitamin C than normal, this vitamin will regulate and stabilize stem cell function and suppress the chances of developing leukemia.

Physician Daniel Couturier commented, “Available studies indicate that vitamin C, at doses of 4 g/kg b.w., a
pancreatic tumor mass reduction of more than 40% could be achieved in a xenograft animal model."

The new research settles the Linus Pauling/Arthur Robinson Cancer and Vitamin C Controversy. Both men were right. While low doses promote cancers, high doses can kill cells that spawn cancers.

The Vitamin C Foundation White Paper for cancer doctors and patients estimates the dosing necessary for CSC-lethal concentrations in the blood. The Foundation encourages oncologists to advise their patients to supplement vitamin C in oral amounts that can achieve at least a 100 micromoles/liter concentration in their blood for as long as possible. The major problem is that the kidney constantly reduces vitamin C concentrations to less than this amount steady state, e.g. 85 micromoles/liter, with a half-life of 30 minutes. Our initial estimates are that 1 gram or less of oral vitamin C creates the concentrations that promote CSC proliferation, and that 4 grams creates the minimum required 100 micromole/litter concentration, at least for a little while.

The specific recommended minimum Vitamin C dosage is 12,000 mg per day:

A 1 g oral dose of AA can raise plasma AA to 130 μmol/L within an hour and such doses at intervals of about two hours throughout the day can maintain ~230 μmol AA/L (Krone, 2002)

Dosages up to 80 grams would be appropriate and safe. Links to our analysis and final report on oral dosing are available at our web site https://vitamincfoundation.org/pdfs/CancerWhitePaper.pdf.

The documentary Cancer Can Be Killed, a Jeff Witzeman film, introduces another theory that may explain how vitamin C works to kill cancer. Cancer requires fuel for its rapid cell division, and both its primary fuel, glucose, and vitamin C enter cells via insulin transport. If cancer patients lower their glucose intake and raise their vitamin C intake, the large amount of Vitamin C entering cancer cells becomes a “Trojan Horse.” The cancer tumors are not able to use the massive dosage of vitamin C they have taken in for energy. This wonderful documentary is available for free to Amazon Prime members, and is only $1.99 otherwise.

Robert Fonorow, Inteligent*Vitamin*C Inc, http://immortalcellsciences.com, +1 630-983-6707, [email protected]

Modal title

Foundation White Paper
View PDF
Foundation White Paper
Foundation White Paper

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.